';

HPV

Diagnostics in any setting

Giving health workers the ability to screen and treat in a single visit

Our HPV assay will bring the power of molecular diagnostics to the point-of-care, making molecular diagnostics accessible to patients worldwide.

The Problem

HPV is a sexually transmitted virus that infects cells and can result in precancerous lesions and cancer.

HPV is so common that nearly all sexually active men and women get it at some point in their lives, with 23% infected with a high-risk strain.
It is estimated that 85% of cervical cancer cases and deaths occur in low resource settings.
Persistent HPV infections progress to cervical cancer, leading to an estimated 270,000 deaths and 528,000 new cases in 2012.
Affecting relatively young women, HPV is the largest single cause of years of life lost to cancer in low and middle income countries.
84% of global cervical cancer cases occur in low resource countries; a lack of effective HPV and cervical cancer screening programs is a key reason for the higher cervical cancer incidence.

Currently, the most common method of screening in low resource settings is by visual inspection of the cervix [1]. This method is inexpensive but requires high levels of training, and diagnostic quality is hard to maintain [2].

84% of global cervical cancer cases occur in low resource countries; a lack of effective HPV and cervical cancer screening programs is a key reason for the higher cervical cancer incidence [3]. In Sub-Saharan Africa more than 95% of women have never been screened for cervical cancer [1]. In contrast, it was estimated that about 75% of women in higher income nations were screened between 2008 and 2013 [5].

Molecular diagnostics are an alternative to visual screening, however current methods available for wide distribution in low resource settings are limited by cost, infrastructure requirements, expertise, and many are not capable of strain identification.

“Placing tools such as this in the hands of health workers provides women in low-income countries with the same access to early detection that has dramatically reduced cervical cancer-related deaths in higher income countries.”
David Bell
Director of Global Health Technologies at Global Good
“Placing tools such as this in the hands of health workers provides women in low-income countries with the same access to early detection that has dramatically reduced cervical cancer-related deaths in higher income countries.”
David Bell
Director of Global Health Technologies at Global Good
The Solution

Q-POC™’s multiplexed molecular subtyping HPV assay will identify the presence and strain of HPV, in any setting globally.

With the aim of increasing a patient’s access to HPV screening programmes, this simple to use and inexpensive test will harness the power of molecular diagnostics to support crucial screening programmes, particularly in low resource settings.

The HPV test will provide a rapid and accurate diagnosis in minutes, ensuring health workers and patients receive the information they require, helping to tackle loss to follow-up. Coupled with an increase in the availability of treatment programmes in low-resource settings, Q-POC™ will play a significant role in the reducing the mortality rate from cervical cancer.

We are working with The Global Good Fund to develop this assay, ensuring it meets the needs of health workers globally.

QuantuMDx is dedicated to improving and democratising global health by providing transformative diagnostic tools to overburdened healthcare systems.

LEARN MORE

Subscribe to our e-newsletter and keep up to date with QuantuMDx

THE FUTURE OF DIAGNOSTICS

  • DNA-XT™
    Sample Preparation

    Our next generation spin column will purify high-quality DNA for PCR, sequencing and other molecular processes.

  • Diagnostics
    Under the Tree

    Supporting disease eradication efforts with simple and accurate diagnostic testing in the community.

  • Q-POC™
    Portable Diagnostics

    Our portable, battery-operated molecular diagnostic device will provide sample-to-result testing in less than 20 minutes.

  • Internet of Life™
    Networking Disease Data

    Globally distributed Q-POC devices will geotag and anonymise pathogen data, and send it to the cloud for real-time disease and drug resistance monitoring.

Contact

Contact

Contact